Eris Lifesciences (ERIS) Q4 16/17 earnings summary

Executive summary

• FY17 revenue from operations rose 21.5% YoY to ₹7,250 mn, while consolidated PAT increased 116.9% to ₹2,412 mn, despite temporary demonetisation disruption.

• Focus remained on branded formulations for chronic and specialty acute therapies, backed by 80 mother brands and a nationwide presence.

Financial highlights

• Consolidated net revenue from operations was ₹7,249.57 mn vs ₹5,967.13 mn in FY16; total revenue was ₹7,440.69 mn vs ₹6,000.83 mn.

• Consolidated PAT attributable to shareholders was ₹2,412.11 mn vs ₹1,112.16 mn; PBT was ₹2,630.24 mn vs ₹1,212.56 mn.

• Consolidated operating cash flow reached ₹1,998.63 mn vs ₹1,314.79 mn; investing outflow was ₹1,841.09 mn, including fixed-asset and investment purchases.

Outlook and guidance

• Indian pharmaceutical market forecast at 11.6% CAGR to ₹1,922 bn; chronic segment forecast at 13.9% CAGR.

• Priorities include expanding products in existing therapies, specialty engagement, diagnostic-led patient support, lifecycle extensions, productivity and licensing or off-patent opportunities.

• Targeted expansion areas include neurology, dermatology, women's health and osteoarthritis; management expected to sustain growth momentum without quantified company guidance.